Newsbenzinga
What's Going on With Vera Therapeutics Stock on Tuesday?
· Published
Article summary
Vera Therapeutics Phase 3 trial data show that Trutakna significantly reduces kidney disease progression in IgA nephropathy.
An excerpt from the original article.
Comments —
Loading comments…